Ella
(Ulipristal)ApprovedSmall molecule
Ella is one of 47 small molecule programs targeting Endometriosis. It is currently in Approved.
1
Indications
5
Total Trials
0
Active Trials
46
Competitors
10
FDA Applications
NDA/BLA/ANDA regulatory filings
8
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
60 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Danocrine
SanofiApproved
Bayer Aspirin
BayerApproved
Orilissa
AbbViePhase 3
Estrace
Novo NordiskApproved
IC-Green
PProvepharm SAS
Approved
Ketalar
AAultman Health Foundation
Approved
Flagyl
DDePuy Orthopaedics
Approved
Zocor
OOrganon and Co
Approved
Trelstar
OOncoVerity, Inc.
Approved
Implanon
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Uterine Fibroid2 trials
Treatment1 trial
UA Versus UAE in Treatment of Fibroids
Completed·—·Phase 4·NCT04832906·70 enrolled
Regulatory
FDA Approval Timeline[4]
Aug 13, 2010
ELLA
NDA NDA022474
Aug 13, 2010
ELLA
NDA NDA022474
May 2, 2012
ELLA
NDA NDA022474
Jun 12, 2014
ELLA
NDA NDA022474
Jun 27, 2014
ELLA
NDA NDA022474
Aug 28, 2014
ELLA
NDA NDA022474
Mar 10, 2015
ELLA
NDA NDA022474
Apr 7, 2015
ELLA
NDA NDA022474
May 1, 2018
ELLA
NDA NDA022474
Jun 24, 2021
ELLA
NDA NDA022474
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ulipristal. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Ella. U.S. Food & Drug Administration.
- [6]